NewsVandana Singh
Entrada Therapeutics
TRDA · NASDAQ
$4.99+$0.17 (+3.53%)TodayMarket closed ·
Prev close $4.82
Latest news
- Press releaseGlobe Newswire
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
- Press releaseGlobe Newswire
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
- NewsTim Melvin
Alpha Buying: Follow the Money From NVIDIA and Merck
- Press releaseGlobe Newswire
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
- Press releaseGlobe Newswire
INVESTOR ALERT: Investigation of Entrada Therapeutics, Inc. (TRDA) announced by Holzer & Holzer, LLC
- Press releaseGlobe Newswire
TRDA Investors Have Opportunity to Join Entrada Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA
- NewsAvi Kapoor
Dow Dips 350 Points; US Foods Posts Downbeat Earnings
- NewsVandana Singh
Entrada Therapeutics Clinical Trial Data Sparks Brutal Stock Selloff - Here's Why
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Press releaseGlobe Newswire
Entrada Therapeutics Reports First Quarter 2026 Financial Results
- Press releaseGlobe Newswire
Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study
- News
Earnings Summary: Entrada Therapeutics Q4
- News
Entrada Therapeutics Q4 EPS $(0.94) Beats $(1.07) Estimate, Sales $1.299M Miss $13.886M Estimate
- Press releaseGlobe Newswire
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
- Press releaseGlobe Newswire
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study
- News
Entrada Therapeutics Highlights Advancement Of RNA-Based Neuromuscular And Ocular Disease Programs And Cash Runway Into Q3 2027
- News
Entrada Therapeutics Q2 EPS $(1.04) Misses $(0.85) Estimate, Sales $1.950M Miss $9.651M Estimate
- News
Entrada Therapeutics Q1 EPS $(0.42) Beats $(0.76) Estimate, Sales $20.56M Beat $10.17M Estimate
- News
Entrada Therapeutics Q4 2024 GAAP EPS $0.03 Beats $(0.67) Estimate, Sales $37.40M Beat $13.12M Estimate
- NewsVandana Singh
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy
- Press releasePRNewswire
Azenta Announces the Election of Dipal Doshi to its Board of Directors
- News
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
- Press releaseBusiness Wire
āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.